Advanced Flower Capital (AFCG) Q3 2026 earnings review
Advanced Flower Capital grows book value, but loan book shrinks
Advanced Flower Capital lifted its book value per share even as its loan portfolio began to shrink. The business development company, which lends to small and mid-sized companies while winding down older cannabis loans, grew net asset value by $0.30 to $8.55 per share on loan mark-ups and discounted stock buybacks. Chief executive Dan Neville reported $0.16 per share in net investment income, but loan repayments topped new lending by $3.5 million.
| Total investment income | $8.6M -1.5% from last quarter |
|---|---|
| Net investment income per share | $0.16 $0.15 last quarter |
| Net asset value per share | $8.55 +$0.30 from last quarter |
| Net investment fundings | -$3.5M +$8.0M last quarter |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because higher book value and lower overhead were offset by a halt in net loan growth and rising non-cash interest. Gross lending dropped to $4.6 million, while interest added to loan balances instead of paid in cash rose to 11% of revenue by our math. One caution: the press release gave no update on defaulted cannabis loans or the $77 million of debt due in May 2027.
The question now is whether the third-quarter valuation gains reflect real cash recoveries on troubled cannabis loans or optimistic accounting marks ahead of the May 2027 debt maturity. If the gains reflect pending cash exits, the lender can pay down its notes and fund new commercial loans; if not, cash interest will keep shrinking. The loan schedule in the third-quarter Form 10-Q filing will show which loans drove the marks.
🐂 Bull Case
Share Buybacks and Loan Marks Lifted Book Value
Advanced Flower Capital, a business development company (BDC) that lends to small and mid-sized businesses, has focused on rebuilding its net asset value (NAV), the book value of its loans minus debt. Chief executive Dan Neville said the lender grew NAV per share by $0.30 this quarter to $8.55, up from $7.46 at the start of the year.
- Unrealized loan gains after tax: $2.9 million, or $0.13 per share, up from $0.08 in Q2
- Share buybacks: 285,656 shares bought at an average price of $3.46, adding $0.06 per share to NAV
- Retained profit: $0.16 per share in net investment income against a $0.05 cash dividend
Buying back stock at a 58% discount to book value creates an immediate gain for remaining shareholders. Because the lender has already spent $3.8 million of its $5.0 million buyback plan since May, only about $1.2 million of capacity remains unless the board expands it. The unrealized gains also trimmed the gap between what the loans cost and their fair value to $61.5 million.
What to watch: the loan schedule in the third-quarter filing. It will show whether the $2.9 million valuation gain came from cash recoveries on troubled cannabis loans or paper mark-ups.
Lower Overhead and Share Count Lifted Per-Share Profit
Total investment income dipped 1.5% from last quarter to $8.57 million, but net investment income (NII) — the profit left after interest, fees and taxes — edged up 1.6% to $3.54 million. On a per-share basis, NII rose from $0.15 to $0.16, covering the $0.05 quarterly dividend more than three times.
Lower overhead and fewer shares drove the improvement. General, administrative and professional fees — the day-to-day cost of running the fund and paying lawyers — fell by 1.5 percentage points of revenue to 14.3%. Meanwhile, second- and third-quarter stock buybacks cut the average share count by 2.7% from last quarter to 22.58 million.
What to watch: legal and administrative expenses next quarter. Foreclosure work on defaulted cannabis loans can cause professional fees to jump back up without warning.
🐻 Bear Case
New Lending Reversed as Repayments Topped Fundings
Advanced Flower Capital converted from a cannabis real estate trust into a generalist lender in January so it could recycle repayments from old cannabis loans into new industries. Neville said, "We will continue to allocate capital where it earns the best risk-adjusted return." While this shift is supposed to grow the non-cannabis loan book, it also tests whether a small lender can find enough deals.
In the third quarter, the loan book shrank instead of growing. The firm funded $4.6 million across one new borrower ($3.1 million) and four existing borrowers ($1.5 million), while collecting $8.1 million in repayments and amortization. That left net fundings at negative $3.5 million, after positive net fundings of $39.1 million in the first quarter and $8.0 million in the second.
This slowdown matters because older cannabis loans carry higher interest rates than the newer commercial loans replacing them. When repayments outpace new lending, the earning asset base contracts and cannot offset lower yields on new deals. Even adding one new industry this quarter (bringing the total to 18 investments across 5 industries) did not stop the total portfolio cost from falling by $3.3 million.
What to watch: gross fundings and the non-cannabis share of portfolio fair value in the full quarterly report. Another quarter below $10 million in gross fundings would leave interest income shrinking as older loans pay off.
More Interest Arrived as IOU Notes
Headline investment income looked steady at $8.57 million, down 1.5% from $8.69 million in the second quarter. However, a growing share of that revenue came from payment-in-kind (PIK) interest — interest added to a borrower's loan balance rather than paid in cash.
Cash interest income fell 3.7% from last quarter to $7.62 million, while PIK interest rose 21.2% to $0.95 million. By our math, PIK now accounts for 11.1% of total investment income, up from 9.0% in the second quarter and 3.4% in the first. Because the company still pays its external manager an incentive fee based on total net investment income, rising PIK means paying cash fees today on interest that borrowers will not pay until their loans mature.
What to watch: which borrowers generated the $0.95 million of PIK in the quarterly filing's loan schedule. Rising PIK on modified cannabis loans would signal that borrowers still cannot meet cash interest bills.
Quarter-End Revolver Draws Kept Cash High
For a third straight quarter, Advanced Flower Capital ended the period holding more than $100 million in cash alongside large short-term credit line balances. In the first two quarters of 2026, the lender drew heavily on its bank revolver and a credit line from an affiliate owned by its chairman right before quarter-end, only to repay most of both on the first day of the next quarter.
- Quarter-end cash: $102.1 million, or 25.8% of total assets
- Secured bank credit line: $115.0 million drawn, up from $110.0 million in Q2
- Affiliate credit line: $5.0 million drawn, down from $20.0 million in Q2
- Senior unsecured notes: $77.0 million principal due May 2027
The press release does not say whether the company repaid the $115.0 million bank line and $5.0 million affiliate line in early October. Meanwhile, the external manager collected $1.67 million in net management and incentive fees this quarter — 32.1% of pre-fee investment profit by our math — and the release gave no refinancing update on the $77.0 million of notes maturing in May 2027.
What to watch: the subsequent-events footnote in the Form 10-Q. It will show October debt repayments and whether the $77.0 million note refinancing has progressed.
Risks This Quarter Didn't Answer
The earnings release provides summary financial tables, leaving five standing credit and tax questions for the Form 10-Q and earnings call.
- Non-accrual loan share: not in the release (was 35.7% of cost and 22.7% of fair value in Q2); the filing's asset-quality table will show if it stayed below 36%.
- Justice Grown default ($78.8 million principal in Q2): no update on foreclosure or recovery marks.
- Devi Holdings asset sale ($12.5 million term sheet): no word on whether the sale closed or brought in cash.
- Performing cannabis waivers (Story, Theratrue, High End, Natures Medicine): no internal risk-rating breakdown in the release.
- Tax distribution gap: year-to-date NII is $0.52 per share against $0.15 in dividends paid, with no comment on the 90% taxable-income payout rule.
💲 Other KPIs
Weighted average yield on accruing debt investments ticked up 0.1 percentage points from 13.2% in the second quarter. Senior secured first-lien loans — debt backed by a first claim on borrower assets — still made up 100% of the portfolio at fair value.
Leverage net of cash fell from 0.53x in the second quarter and stands near the 0.48x level from the first quarter. Total debt-to-equity dropped from 1.10x to 1.03x as total debt fell $10.0 million to $197.0 million and net assets rose to $191.6 million, lifting regulatory asset coverage from 190% to 197%.
The weighted average interest rate on the lender's own borrowings dipped to 6.2% from 6.3% in the second quarter. Lower average reliance on the higher-cost affiliate credit line ($5.0 million at quarter-end vs $20.0 million in Q2) helped trim quarterly interest expense by 2.8% to $1.87 million.
🔮 Guidance
Unchanged. The board's $5.0 million buyback plan remains in place until the cap is reached or May 4, 2027. After spending $2.8 million in the second quarter and $1.0 million in the third quarter ($3.8 million year-to-date), about $1.2 million of capacity remains by our math. Advanced Flower Capital does not issue revenue or earnings forecasts.
❓ Key Questions
Did the $12.5 million Devi Holdings sale close?
Management previously cited a binding term sheet to sell Devi's Massachusetts and New Mexico assets in 2026, with roughly 80% of proceeds coming to Advanced Flower Capital. The release did not say whether any of the $8.1 million in Q3 repayments came from Devi.
How will the company refinance the May 2027 notes?
The $77.0 million of senior unsecured notes mature in six months. Paying them off with bank revolver capacity would consume liquidity needed for new loans, while refinancing them in today's credit market could raise the company's 6.2% borrowing rate.
Were the quarter-end credit lines repaid again in October?
In Q1 and Q2, the lender drew over $100 million across its bank and chairman-affiliated credit lines for a few days around quarter-end. Investors need to know average intra-quarter debt and why this quarter-end borrowing persists.
Did any modified cannabis loans fall into non-accrual?
Several performing cannabis borrowers — Story, Theratrue, High End and Natures Medicine — needed covenant waivers or extensions earlier this year. The release did not disclose whether non-accruals stayed at three borrowers or rose above 35.7% of portfolio cost.
Will the Regulated Investment Company election force a special dividend?
To qualify for pass-through tax status, the firm must distribute at least 90% of its taxable income. Year-to-date net investment income is $0.52 per share against $0.15 in dividends paid, leaving a $0.37 gap unless tax losses offset it.